TEVA PHARMACEUTICAL INDUSTRIES 'BUY'
Analysts at Jyske Bank maintain their "buy" rating on Teva Pharmaceutical Industries Limited. The target price is set to $51. In a research note published this morning, the analysts mention that the company is witnessing robust growth in the generic business. The sales of Teva Pharmaceutical Industries' Copaxone drug and Ivax's asthma products continue to be impressive, the analysts say.